92
quantification of the tumor burden in humanized models (Fig. 6.3) [ 18 , 22 ]. A
decrease in emission of photons is attributed to the cytotoxic effects of the drug/
therapy as a result of either induction of cell death or a reduction in cell metabolic
ability. BLI has been used in a large number of preclinical, cancer pharmacology
and immunotherapeutic studies such as brain, breast, and lung carcinoma, sarcomas
including multiple myeloma [ 18 , 23 ]. Recently, we used BLI and showed signifi-
cant inhibition in myeloma tumor growth in NOD/SCID/IL2Rγnull-Hu mouse model
after ENK cell therapy, which successfully lead the way for clinical studies in
1.0E+10
1.0E+06
Day 0Day 14
Duration
Luciferase intensity(photons/sec/cm
2 /sr)
Day 28
Day 0 Day 14 Day 28 Luminescence
counts
60000
40000
20000
1.0E+07
1.0E+08
1.0E+09
Fig. 6.3 Bioluminescent imaging of myeloma growth in vivo. Luciferase-transfected OPM2
myeloma cells were engrafted in the NOD/SCID/IL2Rγnull-hu mice. Weekly assessment by live
animal imaging shows a rapid growth of myeloma tumor (upper panel). Bioluminescence intensity
was analyzed immediately and depicted in photons/second/cm^2 /steradian (lower panel).
Bioluminescence intensity was increased with time and was highly correlated with increased cir-
culating hIg (Fig. 6.2)
T.K. Garg and T. Pandey